>>Well, I might attribute the decline today to be more related to the tarceva news. Abgx trying pan with avastin now sounds less likely to be positive.<<
You're referring to the PACCE study?
That's plausible, too, but the chart was starting to tell the tale before today. Of course, it could be today's news that leaked . . . though OSI's slight recovery the last couple of days belies that theory. Anyhow, the PACCE study is in metastatic CRC. EGF expression might be different in the two cancers, leading to different outcomes? Nevertheless, it could be a factor, as you say.
cancer.gov
Interestingly, there's a trial that combines Avastin, Tarceva, and Erbitux. It looks really complicated, but with Tarceva apparently not much help, perhaps the trial will be clearer for Erbitux. There are RCC patients in this trial, but who knows how many, and if metastatic? OTOH, if other patients are helped, which drug is it? Or do we care and just be happy the combo regimen (whichever one it was, there are several) worked?
cancer.gov
Cheers, Tuck |
